lysergic acid

Lysergic acid is a tetracyclic ergoline derivative and a key precursor for the synthesis of various ergoline alkaloids, including lysergic acid diethylamide (LSD) and several prescription medications used in neurology and psychiatry. Riverstone Holdings (operating as River Stone Biotech) utilizes synthetic biology and fermentation-based platforms to manufacture lysergic acid as an active pharmaceutical ingredient (API). The company's approach aims to provide a sustainable, scalable, and high-purity supply of this compound, which is traditionally sourced from ergot fungi. While lysergic acid itself is not typically administered as a finished therapeutic, it serves as the essential structural backbone for a wide range of semi-synthetic ergoline derivatives.

Other names

D-lysergic acid(+)-lysergic acid9,10-didehydro-6-methylergoline-8-carboxylic acid